Back
Western Asset Investment Grade Income Fund Vs. Arrowhead Pharmaceuticals, Inc. Industry Stock Comparison
Buy
62
PAI
Western Asset Investment Grade Income Fund
Last Price:
$12.27
Seasonality Move:
0.89%
Sell
46
ARWR
Arrowhead Pharmaceuticals, Inc.
Last Price:
$61.04
Seasonality Move:
-2.16%
Buy
62
Western Asset Investment Grade Income Fund (PAI)
is a Buy
Is Western Asset Investment Grade Income Fund a Buy, Sell or Hold?
-
The current Western Asset Investment Grade Income Fund [PAI] share price is $12.14. The Score for PAI is 62, which is 24% above its historic median score of 50, and infers lower risk than normal.
-
PAI is currently trading in the 60-70% percentile range relative to its historical Stock Score levels.
-
This Score is currently showing a higher than normal reading, suggesting risk levels may be somewhat lower than normal.
Sell
46
Arrowhead Pharmaceuticals, Inc. (ARWR)
is a Sell
Is Arrowhead Pharmaceuticals, Inc. a Buy, Sell or Hold?
-
The current Arrowhead Pharmaceuticals, Inc. [ARWR] share price is $61.03. The Score for ARWR is 46, which is 8% below its historic median score of 50, and infers higher risk than normal.
-
ARWR is currently trading in the 40-50% percentile range relative to its historical Stock Score levels.
-
This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.
PAI Stock Price Chart
What is Western Asset Investment Grade Income Fund's stock price today?
-
The Western Asset Investment Grade Income Fund share price today is $12.14The current trend is relatively stagnant and PAI is experiencing selling pressure, which indicates risk of future bearish movement.
ARWR Stock Price Chart
What is Arrowhead Pharmaceuticals, Inc.'s stock price today?
-
The Arrowhead Pharmaceuticals, Inc. share price today is $61.03Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and ARWR is experiencing selling pressure, which indicates risk of future bearish movement.
PAI Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | -0.11 | Sell |
| Relative Strength Index (14 RSI): | 45.62 | Sell |
| Chaikin Money Flow: | -20505 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (12.04 - 12.4) | Sell |
| Bollinger Bands (100): | (12.26 - 12.66) | Sell |
ARWR Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | -0.31 | Sell |
| Relative Strength Index (14 RSI): | 52.24 | Buy |
| Chaikin Money Flow: | -832975 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (56.52 - 62.66) | Buy |
| Bollinger Bands (100): | (52.16 - 69.78) | Buy |
PAI Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 12.07 | Buy |
| 20-day SMA: | 12.14 | Sell |
| 50-day SMA: | 12.45 | Sell |
| 200-day SMA: | 12.6 | Sell |
| 8-day EMA: | 12.11 | Buy |
| 20-day EMA: | 12.19 | Sell |
| 50-day EMA: | 12.35 | Sell |
| 200-day EMA: | 12.51 | Sell |
ARWR Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 59.99 | Buy |
| 20-day SMA: | 58.47 | Buy |
| 50-day SMA: | 62.54 | Sell |
| 200-day SMA: | 43.35 | Buy |
| 8-day EMA: | 60.24 | Buy |
| 20-day EMA: | 59.83 | Buy |
| 50-day EMA: | 60.7 | Buy |
| 200-day EMA: | 47.94 | Buy |
Western Asset Investment Grade Income Fund Earnings Growth & PAI Earnings Dates
-
Analysts estimate an earnings decrease this quarter of $0.00 per share, a decrease next quarter of $0.00 per share, a decrease this year of $0.00 per share, and a decrease next year of $0.00 per share.
Arrowhead Pharmaceuticals, Inc. Earnings Growth & ARWR Earnings Dates
-
Analysts estimate an earnings decrease this quarter of $0.26 per share, a decrease next quarter of $0.10 per share, a decrease this year of $3.21 per share, and a decrease next year of $1.06 per share.
Western Asset Investment Grade Income Fund Technical Analysis
| Mar 20 | Mar 23 | Mar 24 | Mar 25 | Mar 26 | Mar 27 | Mar 30 | Mar 31 | Apr 1 | Apr 2 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar | Apr | |||||||||
| 20 | 23 | 24 | 25 | 26 | 27 | 30 | 31 | 01 | 02 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
Arrowhead Pharmaceuticals, Inc. Technical Analysis
| Mar 20 | Mar 23 | Mar 24 | Mar 25 | Mar 26 | Mar 27 | Mar 30 | Mar 31 | Apr 1 | Apr 2 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar | Apr | |||||||||
| 20 | 23 | 24 | 25 | 26 | 27 | 30 | 31 | 01 | 02 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||